|
Market Closed -
London S.E.
11:35:04 2025-07-24 EDT
|
5-day change
|
1st Jan Change
|
|
1,238.00 GBX
|
+1.56%
|
 |
+5.27%
|
+20.90%
|
|
02-26 |
Sector Update: Health Care
|
MT
| |
02-26 |
Indivior's Q4 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance
|
MT
| |
02-26 |
Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026
|
CI
| |
02-26 |
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q4 Revenue $358.0M, vs. FactSet Est of $305.6M
|
MT
| |
02-26 |
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.82 per Share, vs. FactSet Est of $0.67
|
MT
| |
02-26 |
Indivior Pharmaceuticals, Inc. announces an Equity Buyback for $400 million worth of its shares.
|
CI
| |
02-26 |
Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
02-25 |
Indivior PLC authorizes a Buyback Plan.
|
CI
| |
01-08 |
Indivior PLC Provides Earnings Guidance for the Full Year 2026
|
CI
| |
01-08 |
Indivior Expects Up to $1.20 Billion in 2026 Net Revenue
|
MT
| |
01-08 |
(INDV) Indivior Expects 2026 Revenue Range $1.13B - $1.2B, vs. FactSet Est of $1.19B
|
MT
| |
11-03 |
Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
|
CI
| |
25-10-30 |
Top Midday Gainers
|
MT
| |
25-10-30 |
Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
25-10-30 |
Indivior Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Outlook Raised - Shares Up Pre-Bell
|
MT
| |
25-10-30 |
Indivior PLC Raises Earnings Guidance for the Year 2025
|
CI
| |
25-10-30 |
Earnings Flash (INDV) Indivior PLC Reports Q3 Revenue $314.0M, vs. FactSet Est of $261.9M
|
MT
| |
25-10-30 |
Earnings Flash (INDV) Indivior PLC Posts Q3 Adjusted EPS $0.72 per Share, vs. FactSet Est of $0.41
|
MT
| |
25-10-15 |
Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open
|
CI
| |
25-10-01 |
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
|
CI
| |
25-07-31 |
Top Midday Gainers
|
MT
| |
25-07-31 |
Indivior PLC Revises Earnings Guidance for the Year 2025
|
CI
| |
25-07-31 |
Indivior Shares Rise After Q2 Adjusted Earnings, Net Revenue Increase; 2025 Net Revenue Guidance Revised
|
MT
| |
25-07-31 |
Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
|
CI
| |
25-07-31 |
Earnings Flash (INDV) Indivior PLC Posts Q2 Adjusted EPS $0.51 per Share, vs. FactSet Est of $0.25
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
